Click Here for 5% Off Your First Aladdin Purchase!

Quinidine - ≥98.0% (contains 5-15% Dihydroquinidine), high purity , CAS No.56-54-2, Channel blocker of K 2P10.1;Channel blocker of K 2P16.1;Channel blocker of K 2P18.1;Channel blocker of K 2P5.1;Channel blocker of K 2P6.1;Channel blocker of K Ca5.1;Channel blocker of K Na1.1;Channel blocker of K Na1.2;Channel blocker of K v10.1;Channel b

  • Moligand™
  • ≥98%
  • contains 5-15% Dihydroquinidine
Item Number
Q109702
Grouped product items
SKUSizeAvailabilityPrice Qty
Q109702-1g
1g
In stock
$21.90
Q109702-5g
5g
In stock
$52.90
Q109702-25g
25g
In stock
$181.90
Q109702-100g
100g
In stock
$653.90

Blocks sodium and potassium channels

Basic Description

Synonymsquinidine|56-54-2|(+)-Quinidine|Conquinine|Pitayine|Chinidin|Conchinin|(8R,9S)-Quinidine|beta-Quinine|Quinidex|Kinidin|(9S)-6'-Methoxycinchonan-9-ol|Conchinine|Cin-Quin|beta-Quinidine|chinidinum|quinidina|Quinicardine|Quinora|(S)-[(2R,4S,5R)-5-ethenyl-1-a
Specifications & PurityMoligand™, ≥98%, contains 5-15% Dihydroquinidine
Biochemical and Physiological MechanismsClass IA antiarrythmic; reduces both Na+and K+channel currents, including INa, IKrand IKs. Prolongs QT and induces torsade de pointes (TdP).
Storage TempStore at 2-8°C,Protected from light,Argon charged
Shipped InWet ice
GradeMoligand™
Action TypeCHANNEL BLOCKER, INHIBITOR
Mechanism of actionChannel blocker of K 2P10.1;Channel blocker of K 2P16.1;Channel blocker of K 2P18.1;Channel blocker of K 2P5.1;Channel blocker of K 2P6.1;Channel blocker of K Ca5.1;Channel blocker of K Na1.1;Channel blocker of K Na1.2;Channel blocker of K v10.1;Channel b

Associated Targets

CYP1A2 Tchem Cytochrome P450 1A2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP1B1 Tchem Cytochrome P450 1B1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CNR1 Tclin Cannabinoid receptor 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP2C19 Tchem Cytochrome P450 2C19 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

DRD2 Tclin D(2) dopamine receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP3A4 Tclin Cytochrome P450 3A4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ESR1 Tclin Estrogen receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

GABRA1 Tclin Gamma-aminobutyric acid receptor subunit alpha-1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NR3C1 Tclin Glucocorticoid receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AVPR1A Tclin Vasopressin V1a receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ABCB1 Tchem Multidrug resistance protein 1 2 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HRH1 Tclin Histamine H1 receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

KCNA7 Tclin Potassium voltage-gated channel subfamily A member 7 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLCO1B1 Tchem Solute carrier organic anion transporter family member 1B1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLCO1B3 Tchem Solute carrier organic anion transporter family member 1B3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLC6A3 Tclin Sodium-dependent dopamine transporter 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLC6A4 Tclin Sodium-dependent serotonin transporter 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PDE4D Tclin cAMP-specific 3',5'-cyclic phosphodiesterase 4D 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PDE3A Tclin cGMP-inhibited 3',5'-cyclic phosphodiesterase A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PTGS1 Tclin Prostaglandin G/H synthase 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PTGS2 Tclin Prostaglandin G/H synthase 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CACNA1C Tclin Voltage-dependent L-type calcium channel subunit alpha-1C 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

DRD3 Tclin D(3) dopamine receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CHRM3 Tclin Muscarinic acetylcholine receptor M3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRA2B Tclin Alpha-2B adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CHRM2 Tclin Muscarinic acetylcholine receptor M2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRA2C Tclin Alpha-2C adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR2A Tclin 5-hydroxytryptamine receptor 2A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADORA2A Tclin Adenosine receptor A2a 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ACHE Tclin Acetylcholinesterase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRA2A Tclin Alpha-2A adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRB1 Tclin Beta-1 adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRA1A Tclin Alpha-1A adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AR Tclin Androgen receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MAOA Tclin Amine oxidase [flavin-containing] A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADORA1 Tclin Adenosine receptor A1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR1A Tclin 5-hydroxytryptamine receptor 1A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADORA3 Tchem Adenosine receptor A3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR3A Tclin 5-hydroxytryptamine receptor 3A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR2B Tclin 5-hydroxytryptamine receptor 2B 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

BCHE Tclin Cholinesterase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

KCNH2 Tclin Potassium voltage-gated channel subfamily H member 2 6 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

OPRD1 Tclin Delta-type opioid receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

OPRK1 Tclin Kappa-type opioid receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

OPRM1 Tclin Mu-type opioid receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

KCNA4 Tclin Potassium voltage-gated channel subfamily A member 4 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

KCND2 Tclin Potassium voltage-gated channel subfamily D member 2 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol
INCHI InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-/m0/s1
InChi Key LOUPRKONTZGTKE-LHHVKLHASA-N
Canonical SMILES COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O
Isomeric SMILES COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O
WGK Germany 3
RTECS VA4725000
PubChem CID 441074
UN Number 2811
Packing Group I
Molecular Weight 324.42
Beilstein 91866
Reaxy-Rn 3654871

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

6 results found

Lot NumberCertificate TypeDateItem
I2004158Certificate of AnalysisJul 12, 2024 Q109702
I2016279Certificate of AnalysisJul 12, 2024 Q109702
G2227342Certificate of AnalysisJun 14, 2022 Q109702
G2227343Certificate of AnalysisJun 14, 2022 Q109702
G2227344Certificate of AnalysisJun 14, 2022 Q109702
G2227345Certificate of AnalysisJun 14, 2022 Q109702

Chemical and Physical Properties

SolubilitySolvent:DMSO, Max Conc. mg/mL: 32.44, Max Conc. mM: 100; Solvent:ethanol, Max Conc. mg/mL: 8.11, Max Conc. mM: 25
SensitivityLight sensitive;heat sensitive
Melt Point(°C)170-175°C

Safety and Hazards(GHS)

Pictogram(s) GHS06
Signal Danger
Hazard Statements

H301:Toxic if swallowed

Precautionary Statements

P321:Specific treatment (see ... on this label).

P405:Store locked up.

P501:Dispose of contents/container to ...

P264:Wash hands [and …] thoroughly after handling.

P270:Do not eat, drink or smoke when using this product.

P330:Rinse mouth.

P301+P316:IF SWALLOWED: Get emergency medical help immediately.

WGK Germany 3
RTECS VA4725000
Reaxy-Rn 3654871
Class 6.1
Merck Index 8060

Related Documents

References

1. White NJ, Looareesuwan S, Warrell DA, Chongsuphajaisiddhi T, Bunnag D, Harinasuta T.  (1981)  Quinidine in falciparum malaria..  Lancet,  (8255): (1069-71).  [PMID:6118523]
2. Milligan CJ, Li M, Gazina EV, Heron SE, Nair U, Trager C, Reid CA, Venkat A, Younkin DP, Dlugos DJ et al..  (2014)  KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine..  Ann Neurol,  75  (4): (581-90).  [PMID:24591078]
3. J A Alloway,M P Salata.  (1995-04-01)  Quinidine-induced rheumatic syndromes..  Seminars in arthritis and rheumatism,  24  ((5)): (315-322).  [PMID:7604299]
4. E J Higginbotham.  (1996-06-01)  Topical beta-adrenergic antagonists and quinidine. A risky interaction..  Archives of ophthalmology (Chicago, Ill. : 1960),  114  ((6)): (745-746).  [PMID:8639090]
5. A A Grace,A J Camm.  (1998-01-01)  Quinidine..  The New England journal of medicine,  338  ((1)): (35-45).  [PMID:9414330]
6. I D Wijnberg,J H van der Kolk.  (2000-08-19)  [Regulation of atrial fibrillation in horses with oral quinidine sulfate. Discussion of the disease picture in a typical case]..  Tijdschrift voor diergeneeskunde,  125  ((14)): (449-452).  [PMID:10948598]
7. Elizabeth S Kaufman.  (2007-05-25)  Quinidine in short QT syndrome: an old drug for a new disease..  Journal of cardiovascular electrophysiology,  18  ((6)): (665-666).  [PMID:17521305]
8. A Corbani,P Manousou,V Calvaruso,I Xirouchakis,A K Burroughs.  (2008-03-25)  Muscle cramps in cirrhosis: the therapeutic value of quinine. Is it underused?.  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver,  40  ((9)): (794-799).  [PMID:18358797]
9. Howard Rosen.  (2009-01-13)  Dextromethorphan/quinidine sulfate for pseudobulbar affect..  Drugs of today (Barcelona, Spain : 1998),  44  ((9)): (661-668).  [PMID:19137121]
10. Felix Yang,Sam Hanon,Patrick Lam,Paul Schweitzer.  (2009-03-03)  Quinidine revisited..  The American journal of medicine,  122  ((4)): (317-321).  [PMID:19249010]
11. Karly P Garnock-Jones.  (2011-04-12)  Dextromethorphan/quinidine: in pseudobulbar affect..  CNS drugs,  25  ((5)): (435-445).  [PMID:21476614]
12. Karran A Phillips,Glenn A Hirsch,David H Epstein,Kenzie L Preston.  (2012-05-18)  Cardiac complications of unwitting co-injection of quinine/quinidine with heroin in an intravenous drug user..  Journal of general internal medicine,  27  ((12)): (1722-1725).  [PMID:22592353]
13. Rajareddy Kallem,Chetan P Kulkarni,Dakshay Patel,Megha Thakur,Michael Sinz,Sheelendra P Singh,S Shahe Mahammad,Sandhya Mandlekar.  (2012-10-16)  A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier..  Drug metabolism letters,  ((2)): (134-144).  [PMID:23061481]
14. Glenna C L Bett,Agnieszka Lis,Hong Guo,MiMi Liu,Qinlian Zhou,Randall L Rasmusson.  (2012-10-16)  Interaction of the S6 proline hinge with N-type and C-type inactivation in Kv1.4 channels..  Biophysical journal,  103  ((7)): (1440-1450).  [PMID:23062336]
15. Shaoxiang Wu,Wei Zeng,Qi Wang,Fu-Xue Chen.  (2012-10-23)  Asymmetric trifluoromethylation of aromatic aldehydes by cooperative catalysis with (IPr)CuF and quinidine-derived quaternary ammonium salt..  Organic & biomolecular chemistry,  10  ((47)): (9334-9337).  [PMID:23085678]
16. Alexander P Gorka,Katy S Sherlach,Angel C de Dios,Paul D Roepe.  (2012-11-02)  Relative to quinine and quinidine, their 9-epimers exhibit decreased cytostatic activity and altered heme binding but similar cytocidal activity versus Plasmodium falciparum..  Antimicrobial agents and chemotherapy,  57  ((1)): (365-374).  [PMID:23114754]
17. Kuniaki Ishii,Ikuo Norota,Yutaro Obara.  (2012-11-21)  Endocytic regulation of voltage-dependent potassium channels in the heart..  Journal of pharmacological sciences,  120  ((4)): (264-269).  [PMID:23165803]
18. Aziza El Harchi,Dario Melgari,Yi Hong Zhang,Henggui Zhang,Jules C Hancox.  (2013-01-10)  Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel..  PloS one,  ((12)): (e52451-e52451).  [PMID:23300672]
19. Qunsheng Guo,John Cong-Gui Zhao.  (2013-01-25)  Highly enantioselective three-component direct Mannich reactions of unfunctionalized ketones catalyzed by bifunctional organocatalysts..  Organic letters,  15  ((3)): (508-511).  [PMID:23343472]
20. Marketa Martinkova,Bozena Kubickova,Marie Stiborova.  (2013-01-29)  Effects of cytochrome P450 inhibitors on peroxidase activity..  Neuro endocrinology letters,  33 Suppl 3  (33-40).  [PMID:23353841]
21. Rajeev Jain,Dhanjai.  (2013-02-07)  Nano graphene based sensor for antiarrhythmic agent quinidine in solubilized system..  Colloids and surfaces. B, Biointerfaces,  105  (278-283).  [PMID:23384690]
22. Sami Viskin,Arthur A M Wilde,Milton E Guevara-Valdivia,Amin Daoulah,Andrew D Krahn,Douglas P Zipes,Amir Halkin,Kalyanam Shivkumar,Noel G Boyle,Arnon Adler,Bernard Belhassen,Edgardo Schapachnik,Farhan Asrar,Raphael Rosso.  (2013-04-16)  Quinidine, a life-saving medication for Brugada syndrome, is inaccessible in many countries..  Journal of the American College of Cardiology,  61  ((23)): (2383-2387).  [PMID:23583244]
23. Stephen M Stahl.  (2013-09-21)  Mechanism of action of dextromethorphan/quinidine:comparison with ketamine..  CNS spectrums,  18  ((5)): (225-227).  [PMID:24050154]
24. Stéphane Boulé,Claude Kouakam,François Brigadeau.  (2013-11-26)  Very prolonged episode of self-terminating ventricular fibrillation in a patient with Brugada syndrome..  The Canadian journal of cardiology,  29  ((12)): (1742-1742).  [PMID:24267814]
25. Sarah K Lawrence,Dung Nguyen,Chet Bowen,Lauren Richards-Peterson,Konstantine W Skordos.  (2014-04-22)  The metabolic drug-drug interaction profile of Dabrafenib: in vitro investigations and quantitative extrapolation of the P450-mediated DDI risk..  Drug metabolism and disposition: the biological fate of chemicals,  42  ((7)): (1180-1190).  [PMID:24748562]
26. Jacek Wójcikowski,Agnieszka Basińska,Władysława A Daniel.  (2014-05-21)  The cytochrome P450-catalyzed metabolism of levomepromazine: a phenothiazine neuroleptic with a wide spectrum of clinical application..  Biochemical pharmacology,  90  ((2)): (188-195).  [PMID:24841887]
27. Laura Kervezee,Robin Hartman,Dirk-Jan van den Berg,Shinji Shimizu,Yumi Emoto-Yamamoto,Johanna H Meijer,Elizabeth C M de Lange.  (2014-06-12)  Diurnal variation in P-glycoprotein-mediated transport and cerebrospinal fluid turnover in the brain..  The AAPS journal,  16  ((5)): (1029-1037).  [PMID:24917180]
28. Klaus Eyer,Michael Herger,Stefanie D Krämer,Petra S Dittrich.  (2014-06-15)  Cell-free microfluidic determination of P-glycoprotein interactions with substrates and inhibitors..  Pharmaceutical research,  31  ((12)): (3415-3425).  [PMID:24928366]
29. Lijun Zhu,Xiawen Liu,Liu Zhu,Xingfei Zhang,Xiaojing Fu,Junjun Huang,Mu Yuan.  (2014-06-20)  Identification of human cytochrome P450 isozymes involved in the metabolism of naftopidil enantiomers in vitro..  The Journal of pharmacy and pharmacology,  66  ((11)): (1534-1551).  [PMID:24944083]
30. Yasuo Uchida,Kentaro Wakayama,Sumio Ohtsuki,Masato Chiba,Tomoyuki Ohe,Yasuyuki Ishii,Tetsuya Terasaki.  (2014-06-21)  Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys..  The Journal of pharmacology and experimental therapeutics,  350  ((3)): (578-588).  [PMID:24947467]
31. Teresa W Tam,Rui Liu,Ammar Saleem,John T Arnason,Anthony Krantis,Pierre S Haddad,Brian C Foster.  (2014-06-28)  The effect of Cree traditional medicinal teas on the activity of human cytochrome P450-mediated metabolism..  Journal of ethnopharmacology,  155  ((1)): (841-846).  [PMID:24971793]
32. Shuoye Yang,Zhixia Qiu,Qiuyang Zhang,Jiayin Chen,Xijing Chen.  (2014-07-18)  Inhibitory effects of calf thymus DNA on metabolism activity of CYP450 enzyme in human liver microsomes..  Drug metabolism and pharmacokinetics,  29  ((6)): (475-481).  [PMID:25030415]
33. Aurelie Vivares,Sandrine Salle-Lefort,Catherine Arabeyre-Fabre,Robert Ngo,Geraldine Penarier,Michele Bremond,Patricia Moliner,Jean-François Gallas,Gerard Fabre,Sylvie Klieber.  (2014-07-30)  Morphological behaviour and metabolic capacity of cryopreserved human primary hepatocytes cultivated in a perfused multiwell device..  Xenobiotica; the fate of foreign compounds in biological systems,  45  ((1)): (29-44).  [PMID:25068923]
34. Ramakrishna Nirogi,Raghava Choudary Palacharla,Venkatesham Uthukam,Arunkumar Manoharan,Surya Rao Srikakolapu,Ilayaraja Kalaikadhiban,Rajesh Kumar Boggavarapu,Ranjith Kumar Ponnamaneni,Devender Reddy Ajjala,Gopinadh Bhyrapuneni.  (2014-07-30)  Chemical inhibitors of CYP450 enzymes in liver microsomes: combining selectivity and unbound fractions to guide selection of appropriate concentration in phenotyping assays..  Xenobiotica; the fate of foreign compounds in biological systems,  45  ((2)): (95-106).  [PMID:25070627]
35. Alberto Massarotti,Silvio Aprile,Valentina Mercalli,Erika Del Grosso,Giorgio Grosa,Giovanni Sorba,Gian Cesare Tron.  (2014-08-01)  Are 1,4- and 1,5-disubstituted 1,2,3-triazoles good pharmacophoric groups?.  ChemMedChem,  ((11)): (2497-2508).  [PMID:25079879]
36. Anwar Anwar-Mohamed,Khaled H Barakat,Rakesh Bhat,Sergei Y Noskov,D Lorne Tyrrell,Jack A Tuszynski,Michael Houghton.  (2014-08-17)  A human ether-á-go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicity..  Toxicology letters,  230  ((3)): (382-392).  [PMID:25127758]
37. Susanna Tse,Louis Leung,Sangeeta Raje,Mark Seymour,Yoko Shishikura,R Scott Obach.  (2014-09-14)  Disposition and metabolic profiling of [(14)C]cerlapirdine using accelerator mass spectrometry..  Drug metabolism and disposition: the biological fate of chemicals,  42  ((12)): (2023-2032).  [PMID:25217486]
38. Na Yu,Jianmin Jiang,Yang Yu,Hong Li,Xiaoyang Huang,Yunzi Ma,Luankun Zhang,Jian Zou,Boyu Zhang,Shaorui Chen,Peiqing Liu.  (2014-09-30)  SLC41A1 knockdown inhibits angiotensin II-induced cardiac fibrosis by preventing Mg(2+) efflux and Ca(2+) signaling in cardiac fibroblasts..  Archives of biochemistry and biophysics,  564  (74-82).  [PMID:25263961]
39. Zoran Rankovic.  (2014-12-17)  CNS drug design: balancing physicochemical properties for optimal brain exposure..  Journal of medicinal chemistry,  58  ((6)): (2584-2608).  [PMID:25494650]
40. Dominik Gartzke,Jürgen Delzer,Loic Laplanche,Yasuo Uchida,Yutaro Hoshi,Masanori Tachikawa,Tetsuya Terasaki,Jens Sydor,Gert Fricker.  (2014-12-20)  Genomic Knockout of Endogenous Canine P-Glycoprotein in Wild-Type, Human P-Glycoprotein and Human BCRP Transfected MDCKII Cell Lines by Zinc Finger Nucleases..  Pharmaceutical research,  32  ((6)): (2060-2071).  [PMID:25522789]
41. Lucy C Stott,Sabine Schnell,Christer Hogstrand,Stewart F Owen,Nic R Bury.  (2014-12-30)  A primary fish gill cell culture model to assess pharmaceutical uptake and efflux: evidence for passive and facilitated transport..  Aquatic toxicology (Amsterdam, Netherlands),  159  (127-137).  [PMID:25544062]
42. Kentaro Yano,Suzune Mita,Kaori Morimoto,Tamami Haraguchi,Hiroshi Arakawa,Miyako Yoshida,Fumiyoshi Yamashita,Takahiro Uchida,Takuo Ogihara.  (2014-12-30)  Multiple Linear Regression Analysis Indicates Association of P-Glycoprotein Substrate or Inhibitor Character with Bitterness Intensity, Measured with a Sensor..  Journal of pharmaceutical sciences,  104  ((9)): (2789-2794).  [PMID:25545612]
43. Chen Zhang,Jing Zhang,Yan-Ping Huang,Zhao-Sheng Liu.  (2015-02-24)  Macromolecular crowding-assisted fabrication of liquid-crystalline imprinted polymers..  Analytical and bioanalytical chemistry,  407  ((10)): (2923-2931).  [PMID:25701416]
44. Shuilin Xie,Ying Jia,Aiming Liu,Renke Dai,Lizhen Huang.  (2015-03-25)  Hypaconitine-induced QT prolongation mediated through inhibition of KCNH2 (hERG) potassium channels in conscious dogs..  Journal of ethnopharmacology,  166  (375-379).  [PMID:25800797]
45. Muhammad Waqas Sadiq,Yasuo Uchida,Yutaro Hoshi,Masanori Tachikawa,Tetsuya Terasaki,Margareta Hammarlund-Udenaes.  (2015-05-02)  Validation of a P-Glycoprotein (P-gp) Humanized Mouse Model by Integrating Selective Absolute Quantification of Human MDR1, Mouse Mdr1a and Mdr1b Protein Expressions with In Vivo Functional Analysis for Blood-Brain Barrier Transport..  PloS one,  10  ((5)): (e0118638-e0118638).  [PMID:25932627]
46. Niels Bjerre Holm,Line Marie Nielsen,Kristian Linnet.  (2015-05-24)  CYP3A4 Mediates Oxidative Metabolism of the Synthetic Cannabinoid AKB-48..  The AAPS journal,  17  ((5)): (1237-1245).  [PMID:26002511]
47. Katsunori Sasahara,Yoshihiko Shimokawa,Yukihiro Hirao,Noriyuki Koyama,Kazuyoshi Kitano,Masakazu Shibata,Ken Umehara.  (2015-06-10)  Pharmacokinetics and Metabolism of Delamanid, a Novel Anti-Tuberculosis Drug, in Animals and Humans: Importance of Albumin Metabolism In Vivo..  Drug metabolism and disposition: the biological fate of chemicals,  43  ((8)): (1267-1276).  [PMID:26055620]
48. Gunnar Bergström,Jonas Christoffersson,Kristin Schwanke,Robert Zweigerdt,Carl-Fredrik Mandenius.  (2015-07-03)  Stem cell derived in vivo-like human cardiac bodies in a microfluidic device for toxicity testing by beating frequency imaging..  Lab on a chip,  15  ((15)): (3242-3249).  [PMID:26135270]
49. Jennifer L Goldman,J Steven Leeder,Leon Van Haandel,Robin E Pearce.  (2015-07-04)  In Vitro Hepatic Oxidative Biotransformation of Trimethoprim..  Drug metabolism and disposition: the biological fate of chemicals,  43  ((9)): (1372-1380).  [PMID:26138612]
50. Kosuke Doki,Yukio Sekiguchi,Keisuke Kuga,Kazutaka Aonuma,Masato Homma.  (2015-07-22)  Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity..  Drug metabolism and pharmacokinetics,  30  ((4)): (257-262).  [PMID:26195225]
51. Sarah J Lucas,David L Armstrong.  (2015-07-22)  Protein phosphatase modulation of somatostatin receptor signaling in the mouse hippocampus..  Neuropharmacology,  99  (232-241).  [PMID:26196943]
52. Leeor Zilbermintz,William Leonardi,Sun-Young Jeong,Megan Sjodt,Ryan McComb,Chi-Lee C Ho,Cary Retterer,Dima Gharaibeh,Rouzbeh Zamani,Veronica Soloveva,Sina Bavari,Anastasia Levitin,Joel West,Kenneth A Bradley,Robert T Clubb,Stanley N Cohen,Vivek Gupta,Mikhail Martchenko.  (2015-08-28)  Identification of agents effective against multiple toxins and viruses by host-oriented cell targeting..  Scientific reports,  (13476-13476).  [PMID:26310922]
53. Jeroen I Stas,Elke Bocksteins,Alain J Labro,Dirk J Snyders.  (2015-10-28)  Modulation of Closed-State Inactivation in Kv2.1/Kv6.4 Heterotetramers as Mechanism for 4-AP Induced Potentiation..  PloS one,  10  ((10)): (e0141349-e0141349).  [PMID:26505474]
54. Laura Hellinen,Sina Bahrpeyma,Anna-Kaisa Rimpelä,Marja Hagström,Mika Reinisalo,Arto Urtti.  (2020-06-21)  Microscale Thermophoresis as a Screening Tool to Predict Melanin Binding of Drugs..  Pharmaceutics,  12  ((6)):   [PMID:32560065]
55. B Olshansky.  (1996-09-01)  Dofetilide versus quinidine for atrial flutter: viva la difference!?.  Journal of cardiovascular electrophysiology,  ((9)): (828-832).  [PMID:8884511]
56. J O Humphries.  (1998-10-28)  Unexpected instant death following successful coronary artery bypass graft surgery (and other clinical settings): atrial fibrillation, quinidine, procainamide, et cetera, and instant death..  Clinical cardiology,  21  ((10)): (711-718).  [PMID:9789690]
57. .  (2005-05-05)  Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan..  Drugs in R&D,  ((3)): (174-177).  [PMID:15869321]
58. Michelle Huston,Michael Levinson.  (2006-10-19)  Are one or two dangerous? Quinine and quinidine exposure in toddlers..  The Journal of emergency medicine,  31  ((4)): (395-401).  [PMID:17046481]
59. Richard Alan Smith.  (2006-12-08)  Dextromethorphan/quinidine: a novel dextromethorphan product for the treatment of emotional lability..  Expert opinion on pharmacotherapy,  ((18)): (2581-2598).  [PMID:17150011]
60. Bernard Belhassen.  (2012-10-16)  Is quinidine the ideal drug for brugada syndrome?.  Heart rhythm,  ((12)): (2001-2002).  [PMID:23063867]
61. Swaroop Kumar Pandey,Hemlata Dwivedi,Sarika Singh,Waseem Ahmad Siddiqui,Renu Tripathi.  (2012-11-10)  Antimalarial interaction of quinine and quinidine with clarithromycin..  Parasitology,  140  ((3)): (406-413).  [PMID:23137860]
62. Pin-Chuang Lai,John D Walters.  (2013-01-01)  Azithromycin kills invasive Aggregatibacter actinomycetemcomitans in gingival epithelial cells..  Antimicrobial agents and chemotherapy,  57  ((3)): (1347-1351).  [PMID:23274657]
63. Pier Luigi Pellegrino,Matteo Di Biase,Natale Daniele Brunetti.  (2013-05-28)  Quinidine for the management of electrical storm in an old patient with Brugada syndrome and syncope..  Acta cardiologica,  68  ((2)): (201-203).  [PMID:23705565]
64. Liping Li,Meijuan Tu,Xi Yang,Siyuan Sun,Xiaodan Wu,Hui Zhou,Su Zeng,Huidi Jian.  (2014-04-30)  The contribution of human OCT1, OCT3, and CYP3A4 to nitidine chloride-induced hepatocellular toxicity..  Drug metabolism and disposition: the biological fate of chemicals,  42  ((7)): (1227-1234).  [PMID:24778366]
65. Lin Yuan,Peipei Jia,Yupeng Sun,Chengcheng Zhao,Xuran Zhi,Ning Sheng,Lantong Zhang.  (2014-05-13)  Study of in vitro metabolism of m-nisoldipine in human liver microsomes and recombinant cytochrome P450 enzymes by liquid chromatography-mass spectrometry..  Journal of pharmaceutical and biomedical analysis,  97  (65-71).  [PMID:24816159]
66. Shinobu Fujii,Chikako Setoguchi,Kouichi Kawazu,Ken-ichi Hosoya.  (2014-07-06)  Impact of P-glycoprotein on blood-retinal barrier permeability: comparison of blood-aqueous humor and blood-brain barrier using mdr1a knockout rats..  Investigative ophthalmology & visual science,  55  ((7)): (4650-4658).  [PMID:24985475]
67. Qiqin Wang,Jun Feng,Hai Han,Peijie Zhu,Huihui Wu,Maria Luisa Marina,Jacques Crommen,Zhengjin Jiang.  (2014-07-08)  Enantioseparation of N-derivatized amino acids by micro-liquid chromatography using carbamoylated quinidine functionalized monolithic stationary phase..  Journal of chromatography. A,  1363  (207-215).  [PMID:24999069]
68. Roslyn Thelingwani,Britta Bonn,Kelly Chibale,Collen Masimirembwa.  (2014-09-16)  Physicochemical and drug metabolism characterization of a series of 4-aminoquinoline-3-hydroxypyridin-4-one hybrid molecules with antimalarial activity..  Expert opinion on drug metabolism & toxicology,  10  ((10)): (1313-1324).  [PMID:25219629]
69. Teresa W Tam,Rui Liu,Ammar Saleem,John Thor Arnason,Anthony Krantis,Brian C Foster.  (2014-09-17)  Cytochrome P450 3A4 and 2D6-mediated metabolism of leisure and medicinal teas..  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques,  17  ((3)): (294-301).  [PMID:25224344]
70. Qin Ru,Xiang Tian,Ming-Shan Pi,Lin Chen,Kai Yue,Qi Xiong,Bao-Miao Ma,Chao-Ying Li.  (2014-11-26)  Voltage‑gated K+ channel blocker quinidine inhibits proliferation and induces apoptosis by regulating expression of microRNAs in human glioma U87‑MG cells..  International journal of oncology,  46  ((2)): (833-840).  [PMID:25420507]
71. Wei Guo,Xiaowei Shi,Wei Wang,Weili Zhang,Junxia Li.  (2014-12-03)  Identification of the rat liver cytochrome P450 enzymes involved in the metabolism of the calcium channel blocker dipfluzine hydrochloride..  Environmental toxicology and pharmacology,  38  ((3)): (901-912).  [PMID:25461550]
72. Yong Zhao,Bent Håvard Hellum,Aihua Liang,Odd Georg Nilsen.  (2015-02-03)  Inhibitory Mechanisms of Human CYPs by Three Alkaloids Isolated from Traditional Chinese Herbs..  Phytotherapy research : PTR,  29  ((6)): (825-834).  [PMID:25640685]
73. Mikiko Shimizu,Masayuki Hashiguchi,Tsuyoshi Shiga,Koichi Nakamura,Hiro-omi Tamura,Mayumi Mochizuki.  (2015-02-18)  Quantitation of pilsicainide in microscale samples of human biological fluids using liquid chromatography-tandem mass spectrometry..  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,  985  (172-179).  [PMID:25687803]
74. Dezhi Kong,Qing Li,Panpan Zhang,Wei Zhang,Yaqin Zhen,Leiming Ren.  (2015-06-29)  The truth about the lower plasma concentration of the (-)-isomer after racemic doxazosin administration in rats: Stereoselective inhibition of the (-)-isomer by the (+)-isomer at CYP3A..  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,  77  (238-245).  [PMID:26116989]
75. Anna Rapacz,Jacek Sapa,Karolina Pytka,Magdalena Dudek,Barbara Filipek,Natalia Szkaradek,Henryk Marona.  (2015-10-21)  Antiarrhythmic activity of new 2-methoxyphenylpiperazine xanthone derivatives after ischemia/reperfusion in rats..  Pharmacological reports : PR,  67  ((6)): (1163-1167).  [PMID:26481536]
76. Nayara Cristina Perez de Albuquerque,Daniel Blascke Carrão,Maísa Daniela Habenschus,Franciele Saraiva Fonseca,Rodrigo Moreira da Silva,Norberto Peporine Lopes,Bruno Alves Rocha,Fernando Barbosa Júnior,Anderson Rodrigo Moraes de Oliveira.  (2020-11-01)  Risk assessment of the chiral pesticide fenamiphos in a human model: Cytochrome P450 phenotyping and inhibition studies..  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,  146  (111826-111826).  [PMID:33127494]
77. Hao Wang,Bingyan Xia,Mei Lin,Yongpeng Wang,Bin Sun,Yuzhu Li.  (2020-12-18)  Succinic acid inhibits the activity of cytochrome P450 (CYP450) enzymes..  Pharmaceutical biology,  58  ((1)): (1150-1155).  [PMID:33327821]

Solution Calculators